Isabelle Mahé: Cancer Site, Bleeding Risk, and Reduced-Dose Apixaban in Cancer-Associated Thrombosis
Isabelle Mahé, Head of Internal Medicine at Louis Mourier Hospital, APHP at Paris Cité University, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Bleeding risk varies according to solid cancer site, with a low risk of CRB in breast cancer (6·2%) and a narrow range across other solid tumours (15·4–18·5%) (original Article recently published in The Lancet Haematology)
Please read our reply just published in The Lancet Haematology!
In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding (APICAT study published in NEJM Group)”
Title 1: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology
Title 2: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J. López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V. Huisman, Frederikus A. Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T. Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 22, 2026, 14:45Seyed Mehrab Safdari: Prenatal Diagnosis in Hemophilia – Two Decades of Progress and Remaining Challenges
-
Oct 22, 2026, 14:39Mahmoud Abdelnabi: Evaluating the Evidence on Elevated Lp(a) and VTE Before Clinical Translation
-
Oct 22, 2026, 14:34David McIntosh: Fundamental Flaws in National Blood Systems Are Root Causes of Failure
-
Oct 22, 2026, 14:32Aurelio Maggio: Bridging Scientific Progress and Equitable Access to SCD Care in Sub-Saharan Africa
-
Oct 22, 2026, 14:26Khaled Musallam: Longevity and Healthy Aging in Thalassemia
-
Oct 22, 2026, 14:26Deise Catamo Vaz: Two Years of Growth and a New Way of Seeing the World of Stroke
-
Oct 22, 2026, 14:24Yara Mohamed: A Silent Killer Plots his Victim’s Death Over Years
-
Oct 22, 2026, 14:19Shailendra Singh: Two Different Pulmonary Embolism Cases, One Critically Important Lesson
-
Oct 22, 2026, 14:14Caitlin Raymond: Estimating Infection Rates After Therapeutic Plasma Exchange in a Large Real-World Population